Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer

详细信息    查看全文

• 作者：Xiaoming Liu ; William C. Cho
• 关键词：Immune checkpoint blockade ; Non ; small cell lung cancer (NSCLC) ; PD ; 1 ; PD ; L1 ; Precision medicine ; Nivolumab (Opdivo) ; Pembrolizumab (Keytruda) ; Atezolizumab (Tecentriq)
• 刊名：Clinical and Translational Medicine
• 出版年：2017
• 出版时间：December 2017
• 年：2017
• 卷：6
• 期：1
• 全文大小：1324KB
• 刊物主题：Medicine/Public Health, general;
• 出版者：Springer Berlin Heidelberg
• ISSN：2001-1326
• 卷排序：6

文摘

Immune checkpoint blockade therapy by targeting the programmed death protein 1/programmed death ligand 1 (PD-L1) axis using antibodies has yielded promising clinical responses in patients with non-small cell lung cancer (NSCLC). However, owing to the dynamic expression of PD-L1, degree of mutational/neoantigen load, intratumoral heterogeneity, infiltrated immune cells of tumor microenvironment of NSCLC, the response rates to these agents are limited, despite several companion diagnostic assays by detecting PD-L1 in tumor cells have been introduced into clinical practice. Therefore, in this era of precision medicine, there is an urgent need for predictive biomarkers to identify NSCLC patients likely to benefit from this novel therapy.